- Trial phase
- Phase 1 / Phase 1/2
- Time to market
- At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
- Why 5/10
- The next hard, dated catalyst is the EORTC-NCI-AACR late-breaking oral presentation on Nov 18-20, 2026 (~3 weeks away), but the top-line data was already disclosed on Sep 9, 2026, so this is a presentation of known results, not a binary catalyst. The next true binary events (End of Phase 2 FDA meeting in Q1 2027; OS data in H1 2027) are 2-8 months out. The drug is the company's lead asset, but at Phase 1 with no PDUFA or registration trial readout imminent, the score of 5 reflects a major value driver without an imminent binary.
The next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.
Price Chart
Executive Summary
PYX-201 (now micvotabart pelidotin / MICVO) is Pyxis Oncology's lead antibody-drug conjugate targeting Extradomain-B Fibronectin in the tumor extracellular matrix, a first-in-concept stromal target rather than a direct cancer cell target. The drug is in Phase 1 monotherapy (NCT05720117) and Phase 1/2 combination (with Keytruda, NCT06795412) trials for advanced solid tumors, primarily recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Updated Phase 1 monotherapy data as of August 18, 2026 showed a 36% confirmed objective response rate and 94% disease control rate at the 5.4 mg/kg dose in 33 efficacy-evaluable patients, with a median PFS of 6.2 months and 12-month OS probability of 79%. The company announced today it will present these data in a late-breaking oral session at the EORTC-NCI-AACR Symposium (Nov 18-20, 2026). However, massive dilution from a ~$103M public offering completed October 2026 (36M new shares plus ~49M warrants) and a cash runway that does not fully fund the planned Phase 3 trial without warrant exercise create significant overhang. The stock trades at ~$1.69 with a mean analyst target of $8.67.
How It Works
An antibody-drug conjugate (ADC) that works like a guided missile: the antibody homes in on a protein (EDB+FN) found in the scaffolding around solid tumors, then delivers a chemotherapy payload (a microtubule inhibitor called an auristatin) directly into the tumor microenvironment. Unlike most ADCs that target cancer cells directly, PYX-201 attacks the supportive tissue (stroma) that tumors need to grow.
Trial Status
The Phase 1 monotherapy trial (NCT05720117, initiated March 2023) is actively recruiting in dose-expansion cohorts. Updated data as of August 18, 2026 from 33 efficacy-evaluable 2L+ R/M HNSCC patients at the 5.4 mg/kg capped dose showed 36% cORR, 94% DCR, median PFS 6.2 months, and 12-month OS probability 79%. The Phase 1/2 combination trial with pembrolizumab (NCT06795412, initiated April 2025, target 220 patients) is also actively recruiting; an early 7-patient cohort showed a 71% cORR and 100% DCR at doses of 3.6 and 4.4 mg/kg. The company plans an End-of-Phase 2 meeting with the FDA in Q1 2027 and a Phase 3 'Headliner' trial in mid-2027.
The Two-Sided Case
Upcoming Catalysts
- Late-breaking oral presentation at EORTC-NCI-AACR Symposium (Nov 18-20, 2026), Phase 1 monotherapy data
- Q3 2026 earnings / corporate update (Nov 17, 2026)
- Updated MICVO + Keytruda combination data (Q4 2026)
- End of Phase 2 meeting with FDA (Q1 2027)
- Overall survival data from Phase 1 monotherapy study (H1 2027)
- Potential special shareholder meeting to approve increased authorized shares for warrant exercise
- Phase 3 'Headliner' trial initiation (mid-2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Pyxis Oncology Press Release PYXS ·Originating report